In 2023, the research team of Tsinghua University published a study in the internationally renowned scientific journal "Oncogene": showing that NMN can limit the growth of triple-negative breast cancer (TNBC) tumors. In addition, NMN also significantly improved the chances of survival after cancer onset and prevented cancer metastasis. The results may hold promise for inhibiting the growth and spread of TNBC.
Breast cancer has overtaken lung cancer as the most common form of cancer, according to the 2020 global cancer report released by the World Health Organization's International Agency for Research on Cancer (IARC). Among all breast cancers, triple-negative breast cancer (TNBC), which is negative for ER, PR, and HER2, is the most difficult to treat, accounting for about 15% of breast cancer cases.
To test how NMN affects TNBC tumors, the researchers injected human TNBC cells into immunodeficient mice and measured tumor volume while administering NMN at a dose of 500 mg/kg/day. At 48 days after tumor cell injection, NMN reduced tumor volume by more than 10 percent compared to tumor-bearing mice not given NMN. In addition, NMN halved tumor growth and spread in lung tissue. These findings support that NMN significantly slows TNBC tumor growth and significantly limits its metastasis to other tissues.
Figure: Compared with the control group, the tumors of the mice in the NMN group were significantly smaller
In addition, the researchers also found that the average lifespan of mice in the NMN group was prolonged by 15%, indicating that NMN can prolong the survival period after the onset of TNBC by inhibiting the proliferation and spread of cancer cells.
Figure: Survival rate of mice in NMN group and control group
Although NMN anti-tumor research has made continuous progress, and clinical studies on healthy people have shown safety, it is not recommended for cancer patients at this stage.